Overview

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma. It will determine if genotype-guided lansoprazole dosing of lansoprazole improves GER and asthma control.
Phase:
Phase 3
Details
Lead Sponsor:
Jason Lang, M.D., M.P.H.
Collaborators:
Nemours Children's Clinic
Thrasher Research Fund
Treatments:
Dexlansoprazole
Lansoprazole